VivoSeq
Other

P2Y12 Inhibitor

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

P2Y12 Inhibitor is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

20/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Recruiting2 · 40%
Unknown status1 · 20%
Terminated1 · 20%
Completed1 · 20%

Clinical Trials

Trial Activity

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD
Recruiting·SSunnybrook Health Sciences Centre·N/A·NCT06714526·100 enrolled
Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving DAPT Undergoing Dental Procedure.
Unknown status·—·Phase 4·NCT03103685·428 enrolled
Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion
Recruiting·SSamsung Medical Center·Phase 4·NCT04014803·3,500 enrolled
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
Terminated·SSamsung Medical Center·Phase 4·NCT03119012·25 enrolled
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02617290·1,900 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)